CooperVision is showcasing a broad slate of scientific papers and posters at the 2026 Netherlands Contact Lens Congress on March 8–9 in Veldhoven. The presentations span every stage of lens wear, from childhood myopia management through presbyopia, underscoring the company’s commitment to evidence-based innovation.

An investigator-initiated study on the MiSight 1 day dual focus design for myopia control reports that young adult participants achieved comparable vision quality and comfort within six months of wear. These results reinforce the lens’s potential to maintain patient satisfaction during the critical adaptation period.

Additional CooperVision-supported studies validate the performance of MyDay®, Biofinity® and Biofinity Energys® spherical lenses and multifocals in comfort, vision and overall wearer satisfaction. Posters also compare practitioner versus consumer perspectives on remote care and identify opportunities for proactive presbyopic fitting aligned with updated clinical guidelines.